Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Xuewu Zhang, Haitao Meng, Gaixiang Xu, Min Yang, Wanzhuo Xie, Juying Wei, Liya Ma, Xingnong Ye, Liping Mao, Wenyuan Mai, Chunmei Yang, Yanling Ren, Hongyan Tong, Yanan Zhu, Xiang Zhang, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6772.

https://doi.org/10.1182/blood-2024-203639

Published: 2024

Journal Articles

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Yanan Zhu, Yunfei Lv, Xingnong Ye, Juying Wei, Lixia Sheng, Ying Lin, Xiang Zhang, Xuewu Zhang, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2024-198711

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2024-201210

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Bo Zhang, Miao Hu, Yanping Zhang, Xinglu Zhou, Jie Jin

Blood (2024) 144 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2024-201190

Published: 2024

Journal Articles

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2024-200064

Published: 2024

Journal Articles

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2024-203722

Published: 2024

Journal Articles

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Ying Huang, Yanan Zhu, Xiang Zhang, Xuewu Zhang, Juying Wei, Xingnong Ye, Yinjun Lou, Min Yang, Chunmei Yang, Wanzhuo Xie, Haitao Meng, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2024-205842

Published: 2024

Journal Articles

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2024-209459

Published: 2024

Journal Articles

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Chunmei Yang, Liping Mao, Juying Wei, Wanzhuo Xie, Xingnong Ye, Min Yang, Jian Huang, De Zhou, Liya Ma, Yinjun Lou, Huafeng Wang, Jie Jin, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6518.

https://doi.org/10.1182/blood-2024-202298

Published: 2024

Journal Articles

Efficacy and Safety of Glofitamab Combined with Tislelizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results

De Zhou, Wenjuan Yu, Xin Huang, Juying Wei, Liping Mao, Xingnong Ye, Ehsan Ghoushi, Xiaolong Zheng, Xuelian Hu, Jie Jin, Wanzhuo Xie, Hongyan Tong

Blood (2024) 144 (Supplement 1): 6496.

https://doi.org/10.1182/blood-2024-198413

Published: 2024

Journal Articles

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Haiyan Zhang, Xiang Zhang, Jinghan Wang, Xuewu Zhang, Yunfei Lv, Yanan Zhu, Juying Wei, Min Yang, Gaixiang Xu, Xingnong Ye, Yinjun Lou, Chunmei Yang, Haitao Meng, Wanzhuo Xie, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6468.

https://doi.org/10.1182/blood-2024-205687

Published: 2024

Journal Articles

Real-World Outcomes in Grade 3B Follicular Lymphoma and Composite Follicular Lymphoma with Diffuse Large B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study in China

Yufei Lv, Xiang Zhang, Yanan Zhu, Juying Wei, Xuewu Zhang, Xingnong Ye, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6328.

https://doi.org/10.1182/blood-2024-202204

Published: 2024

Journal Articles

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Xuewu Zhang, Yanan Zhu, Xiang Zhang, Xingnong Ye, Gaixiang Xu, Liya Ma, Yanling Ren, Liping Mao, Min Yang, Chunmei Yang, Juying Wei, Yinjun Lou, Wenyuan Mai, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2024-204442

Published: 2024

Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin

Blood (2023) 142 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2023-185363

Published: 2023

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6001.

https://doi.org/10.1182/blood-2023-186048

Published: 2023

Journal Articles

Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial

Blood (2023) 142 (Supplement 1): 6314.

https://doi.org/10.1182/blood-2023-189933

Published: 2023

Journal Articles

Chidamide As Maintenance in Peripheral T-Cell Lymphoma for Patients in Response after Induction Therapy: A Single Center Retrospective Study

Yanan Zhu, Juying Wei, Chunmei Yang, Wanzhuo Xie, Yanhong Tong, Wen-Juan Yu, Jie Jin

Blood (2023) 142 (Supplement 1): 6183.

https://doi.org/10.1182/blood-2023-180495

Published: 2023

Journal Articles

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Nianci Chen, Jiajia Pan, Yile Zhou, Liping Mao, Yinjun Lou, Jiejing Qian, Gaixiang Xu, Juying Wei, De Zhou, Lihong Shou, Huang Li, Minchao Yan, Hui Zeng, Cuihua Fan, Gongqiang Wu, Weiying Feng, Hongyan Tong, Jie Jin, Huafeng Wang

Blood (2023) 142 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2023-182806

Published: 2023

Journal Articles

Dual CK1ε/PI3Kδ Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Juying Wei, Wenjuan Yu, Hongyan Tong, Min Yang, Miao Hu, Xingguo Liu, Yizhe Wu, Xinglu Zhou, Jie Jin

Blood (2022) 140 (Supplement 1): 12065.

https://doi.org/10.1182/blood-2022-165195

Published: 2022

NARROW

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

The Efficacy and Safety of Obinutuzumab with Zanubrutinib As First-Line Treatment in Older Patients with Mantle Cell Lymphoma

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Clinical Characteristics and Prognostic Analysis of Patients with Aggressive Mantle Cell Lymphoma：a Single-Center Real-World Study in China

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Efficacy of Polatuzumab Vedotin in Chinese Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis

Efficacy and Safety of Glofitamab Combined with Tislelizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Real-World Outcomes in Grade 3B Follicular Lymphoma and Composite Follicular Lymphoma with Diffuse Large B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study in China

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Small-Dose Trimethoprim-Sulfamethoxazole Prevents Pneumocystis Jiroveci Pneumonia in B-Cell Lymphoma Patients Receiving Chemotherapy: Analysis of a Randomized Controlled Clinical Trial

Chidamide As Maintenance in Peripheral T-Cell Lymphoma for Patients in Response after Induction Therapy: A Single Center Retrospective Study

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Dual CK1ε/PI3Kδ Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only